Tolmar Commits $35M Upfront, Up to $161.5M in Milestones for Alpha Tau's Alpha DaRT Prostate Cancer Rights
DRTS has more than doubled off its 52-week low of $2.81 on elevated volume (1.9× avg).
Summary
Alpha Tau Medical has secured a strategic collaboration with Tolmar for the exclusive U.S. commercialization of its Alpha DaRT therapy for prostate cancer. Tolmar will make an initial $15 million manufacturing investment and a $20 million equity infusion at a 25% premium ($11.99 per share), with potential milestone payments up to $161.5 million. This partnership provides a critical commercialization pathway and significant funding for Alpha Tau's lead product in a major market, building on recent positive clinical data for Alpha DaRT across various cancer types. The premium equity investment from Tolmar signals strong confidence in the therapy's potential.
At the time of this announcement, DRTS was trading at $9.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $785.9M. The 52-week trading range was $2.81 to $11.62. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.